Companies

From therapeutics to advanced instrumentation to contact lens care technology, Alcon is uniquely positioned to continue our aggressive course of developing and producing the most innovative ophthalmic products and technologies.

The Corporation: -

Discover Alcon's Vision and Commitment. From our beginnings in 1945 when Robert D. Alexander and William C. Conner opened a small pharmacy in Fort Worth, to our current state as a $3 billion international pharmaceutical company, we remain committed to offering the best eye care products for professionals and consumers.

Alcon's Future: -

We will build on Alcon's unique people strengths. Alcon will remain a leader in technological innovation, continuing to provide new, unique products for the vision care practitioner.

Demand for Alcon's comprehensive product line will continue to grow as the world population ages. However, the increasing global focus on controlling health care costs, combined with international currency fluctuations brought about by unstable economies, continue to provide challenges.

Unique products have an advantage as health care costs come under greater scrutiny. In the U.S., price is a serious consideration in the undifferentiated product categories, meaning generic use will rise. Fewer physicians will maintain individual practices; group practices, preferred provider organizations or health maintenance organizations with physicians as employees or owners are expanding.

Alcon's strategy to grow in these new market conditions remains steadfast: maintain focus on eye-related products, build on our established competence, while leveraging selected opportunities in the ear (otic) arena. We will maintain our broad, full-line approach to the ophthalmic industry, offering customers the convenience of dealing with a single source for eye care products. Generic ophthalmic pharmaceuticals will remain part of our product line where strategically appropriate.

We will build on Alcon's unique people strengths. While other companies may 'reengineer' their organizations and cut costs by eliminating long-term employees, Alcon benefits from the breadth and depth of experience available in our global organizations. Our growth provides abundant opportunity for personal development, leading to high levels of team achievement and ultimately, greater success.

The company's goal is to make Alcon products available throughout the world; thus becoming the market leader in every market we serve. The lessons learned abroad where price controls have long presented business challenges have now been applied to the U.S., where health care reform is providing similar challenges.

Finally, we intend to be both the low-cost producer and the product quality leader.

Alcon was formed in 1945 and went public through a partial IPO, March 2002.

Our pharmaceutical and surgical research operations are open to new ideas. As such, our operations don't limit the possibility of potential treatments by focusing on any specific area. We welcome ideas that could help us eliminate blindness worldwide. And because we are open to improving upon our existing technology, our door remains open to those leading-edge surgeons and technology companies around the world who know eye health best.

We recognize the speed in time-to-market with vision saving technology only increases when other scientists, technologists and researchers submit their ideas for the latest in surgical therapeutic tools. As such, we welcome global licenses and co-promotion agreements for marketed compounds, preclinical compounds, clinical compounds and surgical devices and technologies related to these areas of interest:

• Cataract
• Dry Eye
• Glaucoma
• Ocular allergy and inflammation
• Ocular infections
• Otic/Nasal
• Refractive
• Retina

http://www.alcon.com/contact-alcon/in-licensing.asp

Alcon research seeks a better understanding of the processes involved in ophthalmic diseases such as glaucoma, allergy, retinal degenerative diseases, and other ocular pathology and is based on "rational drug design". Alcon has produced a number of highly successful new products, including anti-allergy drugs; glaucoma treatments; Disinfecting Solutions; protein remover for contact lenses care; Lens Drops that help prevent protein buildup; anti-inflammatory and anti-infective drugs; steroids; and surgical systems.

Alcon has research collaborations with major general pharmaceutical companies to obtain compounds to treat eye conditions.

Kevin Buehler is president and chief executive officer of Alcon, Inc., the world's largest eye care company. He began serving as chief executive officer on April 1, 2009.

Mr. Buehler began his career with Alcon in August 1984 as a regional sales manager in the Consumer Products Division where he held the positions of national accounts manager, director of national accounts, national sales manager and director of Sales and Marketing. In 1996, he was named director of Alcon's U.S. Managed Care and Falcon Generic Pharmaceutical groups. He gained significant experience with the pharmaceutical and surgical business areas and became vice president in 1998. The following year he returned to the U.S. Consumer Products Division as vice president and general manager.

Mr. Buehler moved to the International Division in January 2002 as vice president and regional manager, Latin America and Caribbean. He was later named area vice president, Latin America, Canada, Australia and Far East. Prior to being named president and CEO, he served as senior vice president, global markets and chief marketing officer.

Prior to joining Alcon, Mr. Buehler held sales positions with The Gillette Company and a retail management position with Snyder Drug Stores.

Mr. Buehler holds a Bachelor of Science degree from Carroll University in Waukesha, Wisconsin, with concentrations in Business Administration and Political Science. He completed the Harvard Program for Management Development in 1993.

=======================================================

Bill Barton is senior vice president, International Markets of Alcon Laboratories, Inc., a subsidiary of Alcon, Inc., the world's largest eye care company. In this role, Mr. Barton is responsible for the management of International Markets and the Global Marketing Committee.

Mr. Barton joined Alcon in 1989 (following the acquisition of CooperVision) as group product director, marketing, Surgical Products. Since that time, he has held positions of increasing responsibility in all divisions including vice president of marketing for Surgical from 1991 - 1995, vice president of marketing in Pharmaceutical from 1996 - 1998, and vice president of sales for Primary Care from 1999 - 2000. In 2001 he returned to the Surgical Division as vice president and general manager. He gained international experience from 2004 - 2007 as vice president/area president of Canada, Australia and Far East. Most recently he served as vice president/area president of U.S. and Global Marketing, a position he has held since 2007.

Mr. Barton began his career in ophthalmology with Allergan Pharmaceuticals in 1978, as a sales representative. In 1982, he joined Syntex Ophthalmics where he various positions in sales and marketing. He joined CooperVision in 1985 which was later acquired by Alcon.

He holds a Bachelor of Science in Business Administration from Southern Utah State University, as well as a Masters of Business Administration from the University of Utah. He is also a graduate of the Harvard Executive Program.

===================================

Richard Croarkin is senior vice president, chief financial officer and corporate strategy of Alcon, the world's largest eye care company. His global responsibilities include management of all financial functions for the company as well as Information Technology, Investor Relations and Strategic Corporate Communications.

Mr. Croarkin joined Alcon from Nestlé Waters North America (NWNA), where he served as executive vice president finance and chief financial officer. With NWNA since 1994, his responsibilities included financial planning, treasury, accounting, controls, credit information systems and acquisitions. Additionally, Mr. Croarkin oversaw the finances of a business unit that experienced a $4.4 billion sales growth under his leadership. Prior to joining NWNA, Mr. Croarkin worked for Pepsi Incorporated for 11 years, where he served in a number of global senior financial positions, including chief financial officer and vice president finance for Pepsi Latin America and Pepsi Canada. Mr. Croarkin began his career with AMAX, Inc., working in treasury, corporate development and planning-related positions.

Mr. Croarkin holds a Master of Business Administration in Finance from The University of Connecticut and a Bachelor of Arts in Economics from Georgetown University. In addition, Mr. Croarkin holds a Diploma of the French Language from Alliance Francaise in Paris, France.

==================================

Sabri Markabi, M.D., is the senior vice president of Research and Development and Chief Medical Officer of Alcon Laboratories, Inc., a subsidiary of Alcon, Inc., the world's largest eye care company. He manages and directs Alcon's global Research and Development efforts and Regulatory Affairs department.

Dr. Markabi was chosen to take over the role of senior vice president research and development and Chief Scientific Officer in March 2008. Dr. Markabi began his career as a staff neurologist on the faculty of the University Hospital in Tours, France. In 1991, he joined CIBA-GEIGY and assumed positions of increasing responsibilities in France, Switzerland, and New Jersey. In 2004 Novartis appointed him vice president, global head of Development for the Ophthalmic Business Unit, were he oversaw the Development organization including R&D strategy, experimental medicine, clinical development and regulatory affairs.

Dr. Markabi received his medical degree in 1982 from the University of Damascus in Syria. He completed his clinical training and obtained the French Certification in neurology, with additional qualifications in neuropsycopharmacology from the University of Pierre et Marie Curie, Paris, France

=====================================

Ed McGough is senior vice president, Global Manufacturing and Technical Operations of Alcon Laboratories, Inc., a subsidiary of Alcon, Inc., the world's largest eye care company. In this role, Mr. McGough is responsible for the company's Manufacturing, Quality Assurance, Engineering, Global Supply Chain, U.S. Distribution, Corporate Purchasing, Safety and Environmental Affairs and Customer Service.

Mr. McGough joined Alcon in April 1991 as a manager of quality assurance and regulatory affairs in the company's Sinking Spring, Pennsylvania facility. Following this role, Mr. McGough held various positions at Alcon in both Fort Worth, Texas and Puerto Rico, including director of quality assurance, director of operations and director of manufacturing. He has also served as vice president and general manager of Fort Worth and Houston manufacturing. Most recently, Mr. McGough served as vice president, Manufacturing, Pharmaceutical Operations, responsible for the company's pharmaceutical plants in United States, Brazil, Mexico, Spain, Belgium and France.

Prior to joining Alcon, Mr. McGough served in various quality engineering/management roles with Baxter Healthcare Corporation. He is also a member of the International Society for Pharmaceutical Engineering and the Parenteral Drug Association.

Mr. McGough earned a Bachelor of Science in Industrial Engineering from Louisiana Tech University in 1983. He is also a 1999 graduate of the Stanford Executive Program.

=========================================

Elaine E. Whitbeck is senior vice president, chief legal officer, general counsel and corporate secretary for Alcon, the world's largest eye care company. Ms. Whitbeck joined Alcon in 1986 and is responsible for all Alcon legal matters, including those pertaining to securities, intellectual property and patents, acquisition and divestiture transactions, employment issues, litigation, transactional matters, environmental law, real estate/construction, computer/internet issues, regulatory concerns (FDA, FTC, PDMA, OSHA), antitrust issues, benefits, banking/treasury, contract administration and records management. Ms. Whitbeck was also elected to the Supervisory Board of WaveLight AG in March 2008.

Prior to joining Alcon, Ms. Whitbeck was the director of legal operations and shareholder services for Mary Kay Cosmetics, Inc., where she handled product liability claims/litigation, antitrust issues and securities-related matters. Previously, she was a trial attorney with the Dallas law firm of Vial, Hamilton, Koch & Knox. Ms. Whitbeck also served as protocol assistant to Secretaries of Defense James Schlesinger and Donald Rumsfeld in Washington, D.C.

Ms. Whitbeck received a Bachelor of Arts, Summa Cum Laude, Phi Beta Kappa, and Echols Scholar, and a Juris Doctor degree from the University of Virginia. She completed the Harvard Business School's Program for Management and Development in 1993.

Ms. Whitbeck served as the statewide president for the Texas General Counsel Forum in 2002 and 2003 and continues to serve on the statewide board. She also serves on the Advisory Board for the SMU Corporate Counsel Symposium, was a 2004 Honoree for the YWCA's Tribute to Women in Business and was honored with a Women of Influence Award for the "2005 Great Women of Texas Event" by the Fort Worth Business Press. Ms. Whitbeck is a board member of Prevent Blindness America - Texas Chapter, the Lena Pope Home (child protection and adoption) and ORBIS International (the "Flying Eye Hospital").

Cary Rayment

Cary Rayment, M.B.A. (Chairman, President and Chief Executive Officer)
Mr. Rayment was appointed to the position of Chief Executive Officer on October 1, 2004, and elected to the Board of Directors and named Chairman on May 3, 2005. He joined Alcon in 1989 (following the acquisition of CooperVision IOL) as Vice President, Marketing, Surgical Products. Since that time, his responsibilities have continued to increase in diversity as well as scope. Mr. Rayment served as Vice President and General Manager, Surgical Products 1991-1995; was named Vice President and General Manager, Managed Care in 1996; became Vice President, International Marketing in 1997 (adding responsibility for Alcon Japan in 1998); and returned to the Surgical Division as Vice President and General Manager in 2000. He was made Senior Vice President, US, in 2001. Mr. Rayment began his career with the Kendall Company in 1974, where he served in a variety of sales and marketing positions. In 1983, he joined CooperVision IOL as Director of Sales and Marketing, and was promoted to Vice President of Marketing. Mr. Rayment holds a BS in Education from the University of Washington in Seattle, as well as an MBA from the University of Kansas in Lawrence, Kansas. He is a graduate of the Harvard Program for Management Development.

Dr. Werner Bauer

Dr. Bauer joined the Alcon, Inc. board in March 2002 and has served as Executive Vice President, Technical, Production, Environment and R&D of Nestlé since May 2002. In February 2007, he was appointed Chief Technology Officer, Head of Innovation, Technology R&D. Dr. Bauer began his career with Nestlé in 1990 as Head of Nestlé Research Center in Lausanne, Switzerland. In 1996, he became Head of R&D worldwide. In 1998, he moved to South Africa as Technical Manager for Nestlé South and East Africa and in 2000 he took over the position of Managing Director, Nestlé South and East Africa. Dr. Bauer is Chairman and a director of Sofinol S.A. and Vice Chairman and a director of Life Ventures S.A. and Nutrition-Wellness Venture AG. Dr. Bauer also serves as a director of L'Oréal S.A. and Uprona (Canada) Ltd. He is a member of the Supervisory Board of Cereal Partners Worldwide (CPW) and Chairman of the Supervisory Board of Nestlé Deutschland AG. Dr. Bauer is a member of the Board of Trustees of the Bertelsmann Foundation, Germany, and a board member of the Swiss Society of Chemical Industries, Switzerland.

Francisco Castañer

Mr. Castañer joined the Alcon, Inc. board in July 2001. He has served as Executive Vice President, Pharmaceutical and Cosmetic Products, Liaison with L'Oréal S.A., Human Resources and Corporate Affairs of Nestlé since 1997. In 1987, Mr. Castañer was named Managing Director and in 1991 Vice President of the Board of Nestlé España S.A., holding this position until his transfer to Switzerland and his promotion to Executive Vice President of Nestlé in June 1997. Prior to 1987, Mr. Castañer was employed by Nestlé in various capacities both in Switzerland and in Spain. Mr. Castañer began his career with Nestlé in the Market Research Department of Nestlé España S.A. in 1964. Mr. Castañer serves as a director of Galderma Pharma S.A., L'Oréal S.A. and Uprona (Canada) Ltd.

Paul  Bulcke

Paul Bulcke joined the Alcon, Inc. board in May 2008. He is a member of the Board of Directors of Nestlé S.A. and serves as Nestlé's chief executive officer. He was elected to Nestlé's board and appointed to his position on April 10, 2008. Mr. Bulcke has had a long and distinguished career within the Nestle group since 1979, where he advanced through the sales and marketing divisions and then into regional executive management. Most recently, Mr. Bulcke was Executive Vice President and Director for Zone Americas in addition to serving as Co-Chairman of Beverage Partners Worldwide S.A. and Co-Chairman of the Supervisory Board of Cereal Partners Worldwide. Mr. Bulcke graduated from the University of Leuven as a Commercial Engineer and obtained his post graduate in Management at the University of Gent in Belgium.

James  Singh

Mr. Singh joined the Alcon, Inc. board in July 2008 following the closing of the sale of the 24.85 percent minority interest of Alcon, Inc. by Nestlé S.A. to Novartis AG.

In 2008, Mr. Singh was appointed Executive Vice President and Chief Financial Officer of Nestlé S.A. He began his career in 1977 as a financial analyst for Nestlé Canada. From 1980 to 1995 he held various positions relating to finance and treasury in Nestlé Canada. Between 1995 and 2000 he was Executive Vice President and Chief Financial Officer of Nestlé Canada. Between 2000 and 2008 he was Senior Vice President, Acquisitions and Business Development of Nestlé S.A. during which period he was, amongst others, involved in Alcon's IPO in 2002. Mr. Singh graduated as Bachelor of Social Science from the University of Guyana and obtained his Master of Business Administration at the University of Windsor in Canada. In 1980, Mr. Singh graduated as Certified Management Accountant.

Daniel  Vasella

Dr. Vasella joined the Alcon, Inc. board in July 2008 following the closing of the sale of the 24.85 percent minority interest of Alcon, Inc. by Nestlé S.A. to Novartis AG.

Since 1996 Dr. Vasella has served as Chief Executive Officer of the Novartis Group and as executive member of the Board of Directors of Novartis AG. In 1999, he additionally was appointed Chairman of the Board of Directors of Novartis AG. Dr. Vasella graduated with an M.D. from the University of Berne in 1979. After holding a number of medical positions in Switzerland, he joined Sandoz Pharmaceuticals Corporation in the U.S.A. in 1988. From 1993 to 1995, Dr. Vasella advanced from Head of Corporate Marketing to Senior Vice President and Head of Worldwide Development to Chief Operating Officer of Sandoz Pharma Ltd. In 1995 and 1996, Dr. Vasella was a member of the Sandoz Group Executive Committee and Chief Executive Officer of Sandoz Pharma Ltd. Dr. Vasella is a member of the Board of Directors of Pepsico, Inc., United States, a member of the Board of Dean's Advisors at the Harvard Business School, and a member of the INSEAD Board of Directors.

Kevin J. Buehler

Kevin Buehler is president and chief executive officer of Alcon, Inc., the world's largest eye care company.  He began serving as chief executive officer on April 1, 2009.

Mr. Buehler began his career with Alcon in August 1984 as a regional sales manager in the Consumer Products Division where he held the positions of national accounts manager, director of national accounts, national sales manager and director of Sales and Marketing. In 1996, he was named director of Alcon's U.S. Managed Care and Falcon Generic Pharmaceutical groups. He gained significant experience with the pharmaceutical and surgical business areas and became vice president in 1998. The following year he returned to the U.S. Consumer Products Division as vice president and general manager.

Mr. Buehler moved to the International Division in January 2002 as vice president and regional manager, Latin America and Caribbean. He was later named area vice president, Latin America, Canada, Australia and Far East. Prior to being named president and CEO, he served as senior vice president, global markets and chief marketing officer.

Prior to joining Alcon, Mr. Buehler held sales positions with The Gillette Company and a retail management position with Snyder Drug Stores.

Mr. Buehler holds a Bachelor of Science degree from Carroll University in Waukesha, Wisconsin, with concentrations in Business Administration and Political Science. He completed the Harvard Program for Management Development in 1993.

Hermann  Wirz

Hermann Wirz is chief accounting officer (senior vice president and head of group accounting & reporting) for Nestlé S.A. Mr. Wirz began his career in 1968 in financial and management accounting for Electrical Company Lucerne Switzerland. From 1969 through 1971, he held a management accounting position for Shell Switzerland. Mr. Wirz joined Nestlé in 1972 and worked in industrial accounting and budgeting functions for Nestlé England, Spain and Venezuela. He subsequently was appointed manager operational control Latin America for Nestec Switzerland in 1980 and in 1984 was promoted to director of finance & control for Nestlé Peru and for Nestlé Venezuela in 1989. Mr. Wirz was appointed executive vice president and chief financial officer of Nestlé Mexico in 1995 and served in that position through 2000. He achieved his degree in Business Administration in Lucerne, Switzerland, and has completed the Programme for Executive Development at the International Institute for Management Development (IMD) in Lausanne, Switzerland.

Thomas G. Plaskett

Mr. Plaskett joined the Alcon, Inc. board in May 2003. In September 2003, the Board affirmed Mr. Plaskett as the "audit committee financial expert." Since 1991, Mr. Plaskett has served as Chairman of Fox Run Capital Associates, a private consulting firm, focusing on financial advisory and consulting services for emerging companies. Previously, he was Chairman, President and Chief Executive Officer of Pan Am Corporation from 1988 to 1991, and President and Chief Executive Officer of Continental Airlines from 1986 to 1987. Also, during the period from 1974 to 1986, he held several senior management positions at American Airlines and AMR Corporation, including Senior Vice President of Marketing and Senior Vice President of Finance and Chief Financial Officer. He also was Vice-Chairman of Legend Airlines from 1996 to 2000. Mr. Plaskett was elected to the board of directors of Greyhound Lines, Inc., in May 1994, and served as Interim President and Chief Executive Officer of the company for a period in late 1994. He was elected Chairman of the board in 1995 and served in that role until the company was sold in March 1999. Mr. Plaskett is the non-executive Chairman of Novell Corporation; non-executive Chairman of Platinum Research Organization; director of RadioShack Corporation; and a director of several privately held companies.

Lodewijk J.R. de Vink

Mr. de Vink joined the Alcon, Inc. board in March 2002. Mr. de Vink has served as Founding Partner of Blackstone Health Care Partners since April 2003. Prior to that, he was Chairman, International Health Care Partners from November 2000. Mr. de Vink was formerly Chairman, President and CEO of Warner-Lambert Company. Mr. de Vink is a member of the board of directors of Roche Holding AG and Flamel Technologies S.A. Mr. de Vink is also a member of Sotheby's International Advisory Board and a member of the European Advisory Council of Rothschild & Cie.

Joan  W.  Miller, M.D

Joan W. Miller, M.D. is chief and chair of ophthalmology and Henry Willard Williams professor of ophthalmology at the Massachusetts Eye and Ear Infirmary and Harvard Medical School. Dr. Miller's research interests are focused on ocular neovascularization, particularly as it relates to macular degeneration and diabetic retinopathy, including the role of growth factors, the development of antiangiogenic therapy and photodynamic therapy. Dr. Miller has received numerous awards, including the Rosenthal Award of the Macula Society, the Retina Research Award from the Club Jules Gonin and the Alcon Research Institute Award. Dr. Miller's professional affiliations include the American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, Inc. (ARVO) and the New England Ophthalmological Society (NEOS). Dr. Miller earned her Bachelor of Science degree from the Massachusetts Institute of Technology and her medical degree from Harvard Medical School.